REVANCE THERAPEUTICS LTD
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 597
- Market Cap
- $685.5M
- Website
- http://www.revance.com
Clinical Trials
29
Active:0
Completed:26
Trial Phases
2 Phases
Phase 2:20
Phase 3:8
Drug Approvals
2
NMPA:1
FDA:1
Drug Approvals
Botulinum Toxin Type A for Injection
- Product Name
- 注射用A型肉毒毒素
- Approval Number
- 国药准字SJ20240041
- Approval Date
- Sep 3, 2024
NMPA
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 2
20 (71.4%)Phase 3
8 (28.6%)Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06411002
- Locations
- 🇺🇸
Revance, Nashville, Tennessee, United States
Teosyal RHA® Histology and Intradermal Implantation Evaluation Study
- Conditions
- Histology
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04846530
- Locations
- 🇨🇦
Woodbridge, Ontario Site, Woodbridge, Ontario, Canada
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
Phase 2
Completed
- Conditions
- Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04259086
- Locations
- 🇺🇸
Site 1, Manhattan Beach, California, United States
🇺🇸Site 3, San Diego, California, United States
🇺🇸Site 7, Santa Monica, California, United States
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Phase 2
Completed
- Conditions
- Lateral Canthal Lines
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03911102
- Locations
- 🇺🇸
Sacramento, CA Site, Sacramento, California, United States
🇺🇸Sarasota, FL Site, Sarasota, Florida, United States
🇺🇸Itasca, IL Site, Itasca, Illinois, United States
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
Phase 2
Completed
- Conditions
- Plantar Fasciitis
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT03825315
- Locations
- 🇺🇸
Aung Foot Health Clinic, Tucson, Arizona, United States
🇺🇸Sacramento Foot and Ankle Center, Inc, Carmichael, California, United States
🇺🇸Bay Area Foot Care, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found